Summary
The concentration of estrogen receptor protein (ER) in 113 primary or metastatic breast cancers was studied. ER was found to be correlated with the age of the patient. The ER values were generally lower in premenopausal patients (5.6 fmol/mg cytosol protein) than in postmenopausal patients (32.8 fmol/mg cytosol protein). The ER values of perimenopausal patients (0–5 years since the last menstrual period) were heterogeneous but generally closer to those of the premenopausal patients. Use of the ER determination for allocation of the patients either to hormonal (tamoxifen or nandrolonedecanoate) or to cytostatic (adriamycin-cyclophosphamide or Cooper's regimen) therapy was shown to result in highly satisfactory clinical response rates (including complete and partial remissions and stabilized disease) of 68% and 67%, respectively. The practical limit of ER concentration for selection is between 3 and 10 fmol/mg cytosol protein in breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Allegra JC, Lippman ME, Thompson EB, Simon R, Barlock A, Green L, Huff KK, Do HMT, Aitken SC, Warren R (1980) Estrogen receptor status: an important variable in predicting response to endocrine therapy in metastatic breast cancer. Eur J Cancer 16:323–331
Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Ann Biochem 72:248–254
Byar DP, Sears ME, McGuire WL (1979) Relationship between estrogen receptor values and clinical data in predicting the response to endocrine therapy for patients with advanced breast cancer. Eur J Cancer 15:299–310
Kiang DT, Ferring DH, Goldman AI, Ascensao VP, Kennedy BJ (1978) Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer. N Engl J Med 299:1330–1334
Kiang DT, Ferring DH, Gay J, Goldman AI, Kennedy BJ (1980) Estrogen receptor status and response to chemotherapy in advanced breast cancer. Cancer 46:2814–2817
Leclercq G, Heuson JC (1977) Therapeutic significance of sex-steroid hormone receptors in the treatment of breast cancer. Eur J Cancer 13:1205–1215
Lippman ME, Allegra JC (1978) Estrogen receptor and endocrine therapy of breast cancer. Engl J Med 299:930–933
Lippman ME, Allegra JC, Thompson EB, Simon R, Barlock A, Green L, Huff KK, Do HM, Aitken SC, Warren R (1978b) The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med 298:1223–1228
McGuire WL (1978) Steroid receptors in human breast cancer. Cancer Res 38:4289–4291
McGuire WL (1979) Therapeutic significance of hormonal receptor assays. Reviews on Endocrine-Related Cancer [Suppl] 3:41–49
McGuire WL (1980) Steroid receptors and breast cancer. Hosp Pract 15:83–88
McGuire WL, Horwitz KB, Pearson OH, Segaloff A (1977) Current status of estrogen and progesterone receptors in breast cancer. Cancer 39:2934–2947
Miller AB, Hoogstraten B, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–217
Raam S, Gelman R, Cohen JL (1981) Estrogen receptor assay: inter-laboratory and intralaboratory variations in the measurement of receptors using dexctran-coated charcoal technique. Eur J Cancer 17:643–649
Vihko R, Jänne O, Kontula K, Syrjälä P (1980) Female sex steroid receptor status in primary and metastatic breast carcinoma and its relationship to serum steroid and peptide hormone levels. Int J Cancer 26:13–21
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Johansson, R., Vanharanta, R. & Söderholm, J. Estrogen receptors in mammary cancer: Correlation with Age, menopausal status, and response to therapy. J Cancer Res Clin Oncol 107, 221–224 (1984). https://doi.org/10.1007/BF01032611
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01032611